19 July 2022 - PLG0206 has the potential to be the first approved therapy specifically indicated for the treatment of peri-prosthetic joint infection.
Peptilogics today announced that the U.S. FDA has granted fast track designation to the company’s lead drug candidate, PLG0206, for the treatment of peri-prosthetic joint infection.